Efficacy and Safety of Dabigatran Compared with Warfarin in Relation to Baseline Renal Function in Patients with Atrial Fibrillation: A RE-LY Trial Analysis
Atrial Fibrillation Saturday, December 14th, 2013CIRCULATIONAHA: December 9, 2013
Background—Renal impairment increases the risk of stroke and bleeding in patients with atrial fibrillation. In the RE-LY trial dabigatran, with approximately 80% renal elimination, displayed superiority over warfarin for prevention of stroke and systemic embolism in the 150 mg dose, and significantly less major bleeding in the 110 mg dose in 18,113 patients with non-valvular atrial fibrillation. This pre-specified study investigates these outcomes in relation to renal function. Read more
